

Why aren't there kinase-targeting drugs for every disease?

Taking them beyond oncology

Amy Donner (SGC)
Moderator

Panelists

Kumar Saikatendu (Takeda)

John Mathias (Pfizer)


Saul Rosenberg (AbbVie)

David Drewry (SGC UNC)



Imatinib (Gleevec/Glivec)



- * Inhibits BCR-ABL fusion kinase
- * Approved in 2001 (FDA/EMA) for CML
- * First approved kinase inhibitor (KI) and targeted drug
- * Impact for patients: with subsequent KIs, converted CML from lethal disease to a chronically managed one




Kinase inhibitors today

- * 31 FDA-approved kinase inhibitors
- * 27 approved for oncology
- * 3 approved for use outside of oncology:
 - * ruxolitinib (Jakafi/Incyte) JAK inhibitor for Myelodysplastic disorders (2011)
 - * tofacitinib (Xeljanz/Pfizer) JAK inhibitor for Rheumatoid arthritis (2012)
 - * nintedanib (Ofev or Vargatef/BI) for Idiopathic pulmonary fibrosis (2014)

FDA Approval History



Kinase inhibitors in the clinic



Kinase inhibitors: Taking them beyond oncology



* **Kumar Saikatendu**

* **John Mathias**



abbvie

* **Saul Rosenberg**

* **David Drewry**



UNC
CENTER FOR INTEGRATIVE
CHEMICAL BIOLOGY AND
DRUG DISCOVERY

